Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price

SPROStock

$1.20−40.00%52W

Market Cap$69.88M

P/E8.41x

PEG Ratio—

Div yield—

Beta1.49

SPRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-58.12%

Price vs S&P 500 (4W)2.81%

VGM Score54.54

P/E Ratio (Annual)8.41x

Book Value / Share (Quarterly)$0.91

P/TBV (Annual)0.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.68%

Cash Flow / Share (Quarterly)$0.13

Price vs S&P 500 (YTD)-61.32%

Net Profit Margin (TTM)24.90%

EPS (TTM)$0.17

10-Day Avg Trading Volume0.42M

EPS Excl Extra (TTM)$0.17

Revenue Growth (5Y)48.25%

EPS (Annual)$0.15

ROI (Annual)14.52%

Net Profit Margin (5Y Avg)-137.28%

Cash / Share (Quarterly)$0.97

P/E Basic Excl Extra (TTM)4.73x

Revenue Growth QoQ (YoY)-95.61%

P/E Normalized (Annual)8.41x

ROA (Last FY)12.44%

Revenue Growth TTM (YoY)37.24%

EBITD / Share (TTM)$0.23

ROE (5Y Avg)-55.12%

Operating Margin (TTM)22.08%

Cash Flow / Share (Annual)$-0.22

P/B Ratio1.36x

P/B Ratio (Quarterly)2.56x

Net Income / Employee (Annual)$342,900

EV / Revenue (TTM)0.26x

Net Interest Coverage (TTM)-79.03x

ROA (TTM)24.95%

EV / EBITDA (TTM)1.18x

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)7.59x

Quick Ratio (Quarterly)10.23x

3-Month Avg Trading Volume1.27M

52-Week Price Return-40.00%

P/E Incl Extra (TTM)4.73x

Revenue / Employee (TTM)$2,447,400

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)1.08x

Asset Turnover (Annual)0.97x

52-Week High$3.08

Operating Margin (5Y Avg)-138.01%

EPS Excl Extra (Annual)$0.15

Tangible BV CAGR (5Y)-2.14%

26-Week Price Return-46.19%

Quick Ratio (Annual)7.40x

13-Week Price Return-58.62%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.50x

Enterprise Value$15.96M

Revenue / Share Growth (5Y)22.11%

Asset Turnover (TTM)1.00x

Book Value / Share Growth (5Y)-25.34%

Revenue / Employee (Annual)$2,672,100

Pretax Margin (Annual)13.22%

Cash / Share (Annual)$0.71

3-Month Return Std Dev86.06%

Net Income / Employee (TTM)$609,400

ROE (Last FY)14.52%

Net Interest Coverage (Annual)-52.52x

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)2.17x

Receivables Turnover (TTM)7.37x

EV / Free Cash Flow (TTM)2.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.17

Receivables Turnover (Annual)28.73x

ROI (TTM)35.58%

P/S Ratio (TTM)1.18x

Pretax Margin (5Y Avg)-136.71%

Revenue / Share (Annual)$1.13

Tangible BV / Share (Annual)$1.45

Forward P/E7.77x

Price vs S&P 500 (52W)-58.56%

P/E Ratio (TTM)4.73x

Year-to-Date Return-48.50%

5-Day Price Return-1.23%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)-25.35%

Net Profit Margin (Annual)12.83%

Month-to-Date Return2.56%

Cash Flow / Share (TTM)$-0.02

EBITD / Share (Annual)$0.11

Operating Margin (Annual)9.45%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)9.95x

ROI (5Y Avg)-47.92%

P/E Excl Extra (TTM)4.73x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.17

P/TBV (Quarterly)1.17x

P/B Ratio (Annual)2.22x

Pretax Margin (TTM)25.33%

Book Value / Share (Annual)$1.05

Price vs S&P 500 (13W)-60.58%

Beta1.49x

Revenue / Share (TTM)$1.07

ROE (TTM)35.58%

52-Week Low$1.08

vGradeA

gGradeC

mGradeD

vgmGradeC

SPRO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 13, 2025	-$0.25	-$0.13	+48.00%(+$0.12)
Q2 2025	Aug 12, 2025	-$0.38	-$0.03	+92.11%(+$0.35)
Q1 2025	May 13, 2025	-$0.44	-$0.25	+43.81%(+$0.19)

SPRO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.17

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SPROSpero Therapeutics, Inc. Common Stock	A	C	D	$1.20
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Spero Therapeutics, Inc. Common Stock

Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics for multi-drug-resistant bacterial infections and rare diseases. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic for MDR Gram-negative infections; SPR720 for non-tuberculous mycobacterial infections; and SPR206, an intravenous polymyxin candidate for hospital-acquired MDR Gram-negative infections.